Prefer a chat interface with context about you and your work?
Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities
// Ricardo Costa 1 , Rubens B. Costa 1 , Sarah M. Talamantes 2 , Irene Helenoswki 3 , Benedito A. Carneiro 1 , Young Kwang Chae 1 , William J. Gradishar 1 , Razelle Kurzrock 4 and Francis J. Giles 1 1 Division of Hematology Oncology, Northwestern University Feinberg …